To the Editor, I wish to congratulate van Cann and their colleagues [1] in which they investigated medication-related osteonecrosis of the jaw (MRONJ) incidence in patients exposed concomitantly to bone resorption inhibitors (BRIs) and vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs). They concluded that patients receiving concomitant treatment with VEGFR-TKIs and BRIs have a five to ten times higher risk for development of MRONJ compared to patients treated with BRIs alone. However, 86.7 and of 1.9% of all patients in study group (BRIs + VEGFR-TKIs) and control groups (BRIs only) were diagnosed with renal cell carcinoma, respectively. Therefore, it is not generalizable to conclude that concomitant treatment with VEGFR-TKIs and BRIs increase MRONJ incidence in all solid tumors. Actually, incidence rates of MRONJ in both control and study arms were almost similar (10.9 vs. 11.1%, p = 0.95) in the longer follow-up.
